Denali Therapeutics (DNLI) Expected to Post Earnings on Thursday

Denali Therapeutics (NASDAQ:DNLI) is expected to be posting its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.5131) per share and revenue of $2.1540 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.04. During the same quarter in the prior year, the firm posted ($0.78) EPS. On average, analysts expect Denali Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Denali Therapeutics Price Performance

DNLI stock traded up $0.72 during mid-day trading on Tuesday, hitting $23.87. The stock had a trading volume of 184,070 shares, compared to its average volume of 1,773,335. The firm has a fifty day simple moving average of $23.21 and a 200 day simple moving average of $21.13. The firm has a market capitalization of $3.79 billion, a P/E ratio of -8.29 and a beta of 1.01. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 0.01. Denali Therapeutics has a 52 week low of $12.58 and a 52 week high of $27.30.

Institutional Trading of Denali Therapeutics

A number of hedge funds have recently made changes to their positions in the company. State of Wyoming raised its position in Denali Therapeutics by 24.7% in the fourth quarter. State of Wyoming now owns 2,686 shares of the company’s stock worth $44,000 after acquiring an additional 532 shares during the period. ADAR1 Capital Management LLC boosted its stake in Denali Therapeutics by 1.2% in the fourth quarter. ADAR1 Capital Management LLC now owns 52,116 shares of the company’s stock valued at $860,000 after acquiring an additional 600 shares during the last quarter. E Fund Management Co. Ltd. grew its position in shares of Denali Therapeutics by 12.8% during the 2nd quarter. E Fund Management Co. Ltd. now owns 13,612 shares of the company’s stock valued at $190,000 after acquiring an additional 1,543 shares during the period. California State Teachers Retirement System increased its stake in shares of Denali Therapeutics by 1.5% during the 2nd quarter. California State Teachers Retirement System now owns 119,327 shares of the company’s stock worth $1,669,000 after purchasing an additional 1,792 shares during the last quarter. Finally, Headlands Technologies LLC bought a new stake in shares of Denali Therapeutics in the 2nd quarter worth approximately $26,000. 92.92% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. JPMorgan Chase & Co. initiated coverage on shares of Denali Therapeutics in a research report on Monday, July 13th. They set an “overweight” rating and a $29.00 price objective for the company. Deutsche Bank Aktiengesellschaft boosted their price target on Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Leerink Partners reduced their price objective on Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 22nd. Robert W. Baird lifted their target price on Denali Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Finally, UBS Group reissued a “buy” rating on shares of Denali Therapeutics in a report on Tuesday, June 16th. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Denali Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $35.17.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.